Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE: AZD5069 + Enzalutamide in mCRPC
NCT03177187Phase 2Terminated
- Sponsor
- The Institute of Cancer Research
- Start
- Nov 2017
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of azd5069 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoints: Maximum Tolerated Dose at 12 months and Antitumour Activity (Response Rate) at 12 months. Started Nov 2017; status: terminated.
02
Drugs
azd5069
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03177187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177187.